Boston Scientific Corporation (BSX)
NYSE$98.93+0.03 (0.03%)
Market Cap
$145.95B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
399 of 924
Rank in Industry
52 of 118
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BSX Insider Trading Activity
BSX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $4,515 | 1 | 2 |
Sells | $109,622,296 | 55 | 98 |
Related Transactions
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 1 | $4,515 | 3 | $12.4M | $-12.39M |
| Dockendorff Charles J | director | 0 | $0 | 1 | $286,874 | $-286,874 |
| Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 0 | $0 | 1 | $958,717 | $-958,717 |
| Zane Ellen M | director | 0 | $0 | 1 | $1.42M | $-1.42M |
| Woodworth Emily | SVP, Global Controller and CAO | 0 | $0 | 4 | $1.92M | $-1.92M |
| LUDWIG EDWARD J | director | 0 | $0 | 3 | $2.43M | $-2.43M |
| Brown Vance R | SVP, GC and Corp. Secretary | 0 | $0 | 3 | $3.01M | $-3.01M |
| Carruthers Wendy | EVP, Human Resources | 0 | $0 | 9 | $4.94M | $-4.94M |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 0 | $0 | 4 | $5.18M | $-5.18M |
| Sorenson John Bradley | EVP, Global Operations | 0 | $0 | 10 | $7.76M | $-7.76M |
| Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 0 | $0 | 7 | $8.69M | $-8.69M |
| Brennan Daniel J. | EVP and CFO | 0 | $0 | 6 | $19.84M | $-19.84M |
| Mahoney Michael F | Chairman, President & CEO | 0 | $0 | 3 | $40.78M | $-40.78M |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and …
Insider Activity of Boston Scientific Corporation
Over the last 12 months, insiders at Boston Scientific Corporation have bought $4,515 and sold $109.62M worth of Boston Scientific Corporation stock.
On average, over the past 5 years, insiders at Boston Scientific Corporation have bought $1.05M and sold $77.91M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) — $4,515.
The last purchase of 50 shares for transaction amount of $4,515 was made by Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) on 2024‑12‑03.
List of Insider Buy and Sell Transactions, Boston Scientific Corporation
| 2025-03-04 | Sale | Woodworth Emily | SVP, Global Controller and CAO | 482 <0.0001% | $104.63 | $50,432 | -6.23% | |
| 2025-03-03 | Sale | Woodworth Emily | SVP, Global Controller and CAO | 7,149 0.0005% | $104.97 | $750,465 | -6.52% | |
| 2025-02-28 | Sale | Woodworth Emily | SVP, Global Controller and CAO | 9,887 0.0007% | $101.13 | $999,872 | -4.70% | |
| 2025-02-25 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 2,688 0.0002% | $104.00 | $279,552 | -0.77% | |
| 2025-02-24 | Sale | Zane Ellen M | director | 13,586 0.0009% | $104.23 | $1.42M | -3.52% | |
| 2025-02-24 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 4,675 0.0003% | $104.25 | $487,369 | -3.52% | |
| 2025-02-21 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 4,826 0.0003% | $104.64 | $504,993 | -4.52% | |
| 2025-02-19 | Sale | Brennan Daniel J. | EVP and CFO | 67,333 0.0046% | $105.24 | $7.09M | -4.22% | |
| 2025-02-19 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 1,510 0.0001% | $105.35 | $159,079 | -4.22% | |
| 2025-02-19 | Sale | Sorenson John Bradley | EVP, Global Operations | 3,303 0.0002% | $105.19 | $347,443 | -4.22% | |
| 2025-02-18 | Sale | Brennan Daniel J. | EVP and CFO | 17,530 0.0012% | $104.57 | $1.83M | -4.28% | |
| 2025-02-18 | Sale | Sorenson John Bradley | EVP, Global Operations | 2,657 0.0002% | $104.41 | $277,417 | -4.28% | |
| 2025-02-14 | Sale | Sorenson John Bradley | EVP, Global Operations | 1,201 <0.0001% | $106.31 | $127,678 | -4.30% | |
| 2025-02-12 | Sale | Brennan Daniel J. | EVP and CFO | 15,087 0.001% | $105.07 | $1.59M | -2.76% | |
| 2025-02-12 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 13,022 0.0009% | $105.06 | $1.37M | -2.76% | |
| 2025-02-12 | Sale | Sorenson John Bradley | EVP, Global Operations | 6,389 0.0004% | $105.06 | $671,249 | -2.76% | |
| 2025-02-11 | Sale | LUDWIG EDWARD J | director | 12,000 0.0008% | $105.48 | $1.27M | -1.98% | |
| 2025-02-07 | Sale | Sorenson John Bradley | EVP, Global Operations | 6,528 0.0004% | $104.97 | $685,244 | -1.40% | |
| 2025-02-03 | Sale | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 17,313 0.0012% | $101.80 | $1.76M | +1.28% | |
| 2025-01-03 | Sale | Brennan Daniel J. | EVP and CFO | 9,689 0.0007% | $89.86 | $870,636 | +12.77% |
Total: 1173
*Gray background shows transactions not older than one year
Insider Historical Profitability
2.05%
| Mahoney Michael F | Chairman, President & CEO | 1521205 0.1031% | $150.45M | 2 | 25 | +37.05% |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 148148 0.01% | $14.65M | 1 | 20 | |
| LUDWIG EDWARD J | director | 24398 0.0017% | $2.41M | 1 | 4 | +26.95% |
| Dockendorff Charles J | director | 0 0% | $0 | 1 | 2 | +35.4% |
| ABELE JOHN E | Director Emeritus | 500000 0.0339% | $49.45M | 5 | 212 | +7.41% |
*Gray background shows insiders who have made transactions during last year
BSX Institutional Investors: Active Positions
| Increased Positions | 823 | +60.34% | 77M | +5.82% |
| Decreased Positions | 588 | -43.11% | 59M | -4.46% |
| New Positions | 212 | New | 11M | New |
| Sold Out Positions | 98 | Sold Out | 4M | Sold Out |
| Total Postitions | 1,599 | +17.23% | 1B | +1.36% |
BSX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $13.51M | 9.42% | 139.03M | +10M | +8.02% | 2024-12-31 |
| Vanguard Group Inc | $12.91M | 9% | 132.89M | +2M | +1.22% | 2024-12-31 |
| Fmr Llc | $12.87M | 8.97% | 132.44M | -3M | -2.04% | 2024-12-31 |
| State Street Corp | $6.21M | 4.33% | 63.96M | +1M | +1.78% | 2024-12-31 |
| Primecap Management Co/Ca/ | $3.59M | 2.5% | 36.93M | -896,834 | -2.37% | 2024-12-31 |
| Wellington Management Group Llp | $3.51M | 2.45% | 36.17M | +3M | +10.19% | 2024-12-31 |
| Geode Capital Management, Llc | $2.98M | 2.08% | 30.63M | +1M | +3.52% | 2024-12-31 |
| Capital World Investors | $2.71M | 1.89% | 27.9M | +6M | +28.67% | 2024-12-31 |
| Bank Of America Corp /De/ | $2.67M | 1.86% | 27.48M | -669,930 | -2.38% | 2024-12-31 |
| Jpmorgan Chase & Co | $2.55M | 1.78% | 26.24M | +204,261 | +0.78% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.